Research development

New York Blood Center Enterprises Makes Investment to Advance Next-Generation Red Blood Cell Research

Retrieved on: 
Thursday, December 7, 2023
SCD, Sickle cell disease, Research development, Research, Health, Doctor of Philosophy, Education, Genetic disorder, Transfusion medicine, Public, Patient, Intelligence, Organization, Nursing

BOSTON, Dec. 07, 2023 (GLOBE NEWSWIRE) -- New York Blood Center Enterprises ( NYBCe ) announced today that its venture fund, NYBC Ventures , has invested in Functional Fluidics to advance research in sickle cell disease and transfusion medicine.

Key Points: 
  • BOSTON, Dec. 07, 2023 (GLOBE NEWSWIRE) -- New York Blood Center Enterprises ( NYBCe ) announced today that its venture fund, NYBC Ventures , has invested in Functional Fluidics to advance research in sickle cell disease and transfusion medicine.
  • Functional Fluidics , a CLIA-certified diagnostics laboratory specializing in red blood cell health, will use the funds to expand its services to Africa and develop the next generation of red blood cell health assays with the potential to improve diagnostic outcomes in sickle cell disease (SCD), transfusion medicine, and other hematological disease areas.
  • SCD is a globally prevalent genetic disorder that affects more than 100,000 Americans and more than 7 million people worldwide.
  • The investment in Functional Fluidics research is the latest effort in the organization’s mission to expand its humanitarian impact on global public health.

"Endless Mountains - An Exhibition of Art and the Tang Poetry Road: Mountain Trail of Infinite Longing" Held in Beijing

Retrieved on: 
Friday, December 1, 2023
Moon, Beijing Tourism Group, Infinite, Multimedia, CAA, Wind, Poetry, Research development, Emotion, Tang dynasty art, Photography, Exhibit A (art exhibition), Exhibition, Endless Mountains, Gallery, Tang dynasty, Sculpture, Tang poetry, Entertainment, Art, Tang

Beijing plays a key role in bridging the eastern and western parts of the country as well as the past and the present.

Key Points: 
  • Beijing plays a key role in bridging the eastern and western parts of the country as well as the past and the present.
  • It is where the graceful, restrained Tang poetry of Zhejiang in East China and the bold, unconstrained Tang poetry of China's frontiers.
  • It also drew our focus back to "poetry" itself and diverged from the conventional exhibition by doing away with sectioning.
  • The exhibition was a visual, narrative and emotional response to Tang poetry as well as a "poem" composed of artwork.

Sobi to present new data at ASH 2023 Annual Meeting

Retrieved on: 
Monday, November 20, 2023
Blood type, ITP, Swedish Orphan Biovitrum, Society, Ruxolitinib, Research, PNH, Patient, Hemophagocytic lymphohistiocytosis, RDMA, MBA, MD, Research development, ASH, Medical Affairs Bureau

STOCKHOLM, Nov. 20, 2023 /PRNewswire/ -- Sobi® will present new data at the 65th Annual Meeting of the American Society of Hematology (ASH) in San Diego from the 9th to the 12th of December 2023.

Key Points: 
  • STOCKHOLM, Nov. 20, 2023 /PRNewswire/ -- Sobi® will present new data at the 65th Annual Meeting of the American Society of Hematology (ASH) in San Diego from the 9th to the 12th of December 2023.
  • During the meeting several analyses will be presented in patients with haemophilia A, paroxysmal nocturnal hemoglobinuria (PNH), immune thrombocytopenia (ITP), relapsed or refractory diffuse large b-cell lymphoma, myelofibrosis, and haemophagocytic lymphohistiocytosis.
  • "We take pride in our expanded commitment to individuals affected by rare diseases, which we are pleased to highlight at this year's ASH meeting, with research that spans a range of rare and debilitating conditions.
  • "We look forward to collaborating and connecting in person at this year's meeting."

Sobi to present new data at ASH 2023 Annual Meeting

Retrieved on: 
Monday, November 20, 2023
Blood type, ITP, Swedish Orphan Biovitrum, Society, Ruxolitinib, Research, PNH, Patient, Hemophagocytic lymphohistiocytosis, RDMA, MBA, MD, Research development, ASH, Medical Affairs Bureau

STOCKHOLM, Nov. 20, 2023 /PRNewswire/ -- Sobi® will present new data at the 65th Annual Meeting of the American Society of Hematology (ASH) in San Diego from the 9th to the 12th of December 2023.

Key Points: 
  • STOCKHOLM, Nov. 20, 2023 /PRNewswire/ -- Sobi® will present new data at the 65th Annual Meeting of the American Society of Hematology (ASH) in San Diego from the 9th to the 12th of December 2023.
  • During the meeting several analyses will be presented in patients with haemophilia A, paroxysmal nocturnal hemoglobinuria (PNH), immune thrombocytopenia (ITP), relapsed or refractory diffuse large b-cell lymphoma, myelofibrosis, and haemophagocytic lymphohistiocytosis.
  • "We take pride in our expanded commitment to individuals affected by rare diseases, which we are pleased to highlight at this year's ASH meeting, with research that spans a range of rare and debilitating conditions.
  • "We look forward to collaborating and connecting in person at this year's meeting."

Pharmacy Benefit Managers Expose Patients to Negative Health Outcomes, GHLF Updated Studies Shows

Retrieved on: 
Thursday, November 2, 2023
Podcast, Practice Management, Professional Services, Other Health, Other Communications, Health, Pharmaceutical, Entertainment, Communications, Insurance, Finance, JIA, Steroid, Pioneer Institute, PBM, Research development, Government, EST, Mortality, Doctor of Philosophy, Disease, Research, Communication, Caregiver, Risk, Doctor of Pharmacy, Pharmacy, Health policy, Progressive Policy Institute, ESI, CVS, Epilepsy, Patient, MS, CVS Health, Nursing, Pharmaceutical industry, Health insurance

The updated research found that more than half the exclusions (57%) had questionable medical or economic benefits for patients.

Key Points: 
  • The updated research found that more than half the exclusions (57%) had questionable medical or economic benefits for patients.
  • The original peer-reviewed research and its update, which is not yet published, focuses on ESI, the second largest pharmacy benefit manager in the United States.
  • This forced switch to different medications also adds to the challenges patients and their caregivers face, and it ends up costing more for everyone involved in health care — patients, caregivers, employers, and the government.
  • GHLF will host a webinar concerning formulary exclusions and their impact on patients on November 9 at 12 pm EST.

Aduro Clean Technologies Provides Corporate Update and Engages Outside The Box Capital Inc. for Marketing and Investor Relations Services

Retrieved on: 
Thursday, July 6, 2023
ACT, Exercise, Operation, Plastic, Communication, Partnership, CSE, ACTE, Marketing, Lab, Stanford Learning Lab, Research development, Tax, CAD, Polymer, HCT, FSE, Research, HBU, Research and development, OTBC, Chemistry, Development, SOP, Oil, Engineering, Local marketing agreement, Growth, HPU, News, Social media, Safety, Fine chemical, Retail, Interior design, Security (finance), Recycling, Sales, Brightlands School

In addition, there has been substantial progress on the pilot-scale continuous flow reactor for Hydrochemolytic™ Bitumen Upgrading (“R2 Bitumen”).

Key Points: 
  • In addition, there has been substantial progress on the pilot-scale continuous flow reactor for Hydrochemolytic™ Bitumen Upgrading (“R2 Bitumen”).
  • All of these the Company has successfully overcome, driven by the dedication and passion of the Aduro team.
  • In June 2023, Aduro formed its first international hub by establishing Aduro Clean Technologies Europe (“ ACTE ”), marking the first step towards international expansion.
  • The Company also announces that it has entered into a marketing and consulting agreement (the “Marketing Agreement”) with an arm’s length marketing firm, Outside The Box Capital Inc. (“ OTBC ”) of Oakville Ontario, to provide marketing consulting and investor relations services, including marketing services through social media channels and online media distribution.

Anchin Expands Advisory Offerings

Retrieved on: 
Thursday, May 18, 2023
Risk, Tax, Research development, Business, Associate, Wealth management, Manufacturing Advisory Service, CAS, Enterprise Information Technology Data Repository, Financial services, Anchin Abbey

NEW YORK, May 18, 2023 /PRNewswire/ -- Anchin, a premier New York based accounting and advisory firm, is pleased to announce the combination of several specialty practices into its Advisory Services Group to help provide clients with a comprehensive suite of specialized services in tax, business and risk, and technology.

Key Points: 
  • NEW YORK, May 18, 2023 /PRNewswire/ -- Anchin, a premier New York based accounting and advisory firm, is pleased to announce the combination of several specialty practices into its Advisory Services Group to help provide clients with a comprehensive suite of specialized services in tax, business and risk, and technology.
  • Anchin Advisory adds value to every aspect of a business by helping all types and sizes of businesses, investment funds, and high-net-worth families make the most of every opportunity while reducing their risk.
  • Anchin's Advisory offerings are coordinated by three teams that will lead you through complex regulations and transactions, identify tax credit and incentive opportunities, help you navigate leadership transitions, streamline vital business processes, and create technological efficiencies while combating security threats.
  • The Business and Risk Advisory team offers services including Wealth Management (through Anchin affiliate Claris Advisors LLC), Client Accounting Advisory Services (CAS), Litigation Support and Regulatory Compliance and Investigations.

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, January 4, 2023
Oncology, Health, General Health, Research, Science, Biotechnology, Cancer, ImmunoGen, MD, Financial compensation, Research development, Employment, Medical Affairs Bureau, Professional Football Compensation Committee, IMGN, Control, Vaccine, Research

In addition, ImmunoGen announced that on December 30, 2022, the Compensation Committee approved grants of non-qualified stock option awards to purchase an aggregate of 226,950 shares of its common stock (the “Employee Options”) to nine new employees under the Inducement Plan.

Key Points: 
  • In addition, ImmunoGen announced that on December 30, 2022, the Compensation Committee approved grants of non-qualified stock option awards to purchase an aggregate of 226,950 shares of its common stock (the “Employee Options”) to nine new employees under the Inducement Plan.
  • Each option is subject to the terms and conditions of the Inducement Plan and the terms and conditions of a stock option agreement covering the applicable grant.
  • The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of ImmunoGen (or following a bona fide period of non-employment), as an inducement material to such individuals’ entering into employment with ImmunoGen, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
  • The Vasconcelles Options and the Employee Options were granted as such inducement material to Dr. Vasconcelles and the other new employees, respectively, becoming employees of ImmunoGen.

Tanya D'Souza Joins Lathrop GPM as IP Counsel in Minneapolis

Retrieved on: 
Tuesday, July 12, 2022
Genetics, Biochemistry, Research, Patent, Research development, Molecular biology, Private law, University, Biotechnology, Doctor of Philosophy, Intellectual property, 3D printing

MINNEAPOLIS, July 12, 2022 /PRNewswire-PRWeb/ -- Lathrop GPM is pleased to welcome Tanya D'Souza as counsel in the firm's Minneapolis office. D'Souza is joining the firm's Intellectual Property Practice Group.

Key Points: 
  • MINNEAPOLIS, July 12, 2022 /PRNewswire-PRWeb/ -- Lathrop GPM is pleased to welcome Tanya D'Souza as counsel in the firm's Minneapolis office.
  • D'Souza, a registered patent attorney, has worked with clients with a wide range of patent and intellectual property needs.
  • Tanya has provided IP counsel on, among other things, immunology-based, plant, medical device, pharmaceutical, polymer, and composite composition matters.
  • "Lathrop GPM's intellectual property practice delivers excellent legal services, and I am excited to join the team," said D'Souza.

Study Finds All Water-Soluble CBD Formulations Are Not Created Equal For Pharmacokinetic Absorption

Retrieved on: 
Wednesday, June 29, 2022
Research, Fitness & Nutrition, Cannabis, Alternative Medicine, Food, Beverage, Health, Retail, Science, Natural Resources, Science, Cannabinoid, Liver, Trial of the century, Colorado State University, Research development, Food, Autism, Pharmacokinetics, CSU, Risk, Partnership, Sport, Nutrient, Absorption, Calipers, CPG, Research, Pharmaceutical industry, Dietary supplement, CBD

The study also found that consumption of food significantly increased pharmacokinetic absorption of Caliper Foods proprietary formulation of water-soluble cannabidiol (CBD).

Key Points: 
  • The study also found that consumption of food significantly increased pharmacokinetic absorption of Caliper Foods proprietary formulation of water-soluble cannabidiol (CBD).
  • Five different 30 milligram CBD formulations were clinically tested, with Caliper Foods water-soluble CBD exhibiting 282% to 434% greater absorption than oil-based CBD formulations.
  • The study authors concluded that consuming Caliper Foods water-soluble CBD with food increases systemic availability by 2.2X and low-dose CBD probably does not represent a risk to normal liver function.
  • For example, pharmacokinetic data from our specific water-soluble formulations have been used to design and conduct research examining CBD effects on autism, alcohol cravings and enhanced sports performance.